Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9774687 | 0.88 | KMT2A (0.62) | KMT2AMEN1KDM4ENOS2CHRM2 | |
| SCHEMBL2086228 | 0.81 | KMT2A (0.48) | KMT2AMEN1KDM4EL3MBTL1HSD17B10 | |
| SCHEMBL10043041 | 0.79 | KMT2A (1.00) | KMT2AMEN1KDM4ENOS2CHRM2 | |
| SCHEMBL13985725 | 0.78 | KMT2A (0.54) | KMT2AMEN1KDM4ENOS2CHRM2 | |
| SCHEMBL7136567 | 0.78 | SMN1; SMN2 (0.62) | KMT2AMEN1 | |
| SCHEMBL9008815 | 0.78 | KMT2A (0.61) | KMT2AMEN1L3MBTL1 | |
| SCHEMBL10071981 | 0.78 | EPHX2 (0.73) | KMT2AMEN1KDM4EALDH1A1DRD2 | |
| SCHEMBL2211986 | 0.77 | KMT2A (0.51) | KMT2AMEN1KDM4ENOS2CHRM2 | |
| SCHEMBL2212963 | 0.77 | LMNA (0.52) | KMT2AMEN1PKMKDM4EALDH1A1 | |
| SCHEMBL9774779 | 0.76 | KMT2A (0.65) | KMT2AMEN1KDM4ENOS2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114379-B2 | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process | THE GENERAL HOSPITAL CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | THE GENERAL HOSPITAL CORPORATION (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191125-A1 | Diagnostic and Therapeutic Alkyl Piperidine/Piperazine Compounds and Process | NR2E3, DRD2, HCRTR1 | KMT2A 1479/4885MEN1 4462/4885PKM 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.